LB Abnoba

Abnobaviscum M Injection

Home
Products
Abnobaviscum M Injection

Abnobaviscum M Injection
0.02mg/0.2mg/2mg/20mg

Category

Prescription Drug

※ A prescription medicine that requires professional supervision regarding dosage and administration under a physician’ s prescription.

Classification Number

421[Antineoplastic Agent]

Composition and Content

0.02mg : Each 1 mL contains 0.001 mL of concentrated extract of Viscum album(host tree: Malus) (1→50)
0.2mg : Each 1 mL contains 0.01 mL of concentrated extract of Viscum album(host tree: Malus) (1→50)
2mg : Each 1 mL contains 0.1 mL of concentrated extract of Viscum album(host tree: Malus) (1→50)
20mg : Each 1 mL contains 1 mL of concentrated extract of Viscum album(host tree: Malus) (1→50)

Product Details

Product Information

An antineoplastic agent extracted from Viscum album parasitic on the apple tree.

Composition and Content

Abnobaviscum M 0.02 mg Injection : Each 1 mL contains 0.001 mL of concentrated extract of Viscum album (host tree: Malus) (1→50)
Abnobaviscum M 0.2 mg Injection : Each 1 mL contains 0.01 mL of concentrated extract of Viscum album (host tree: Malus) (1→50)
Abnobaviscum M 2 mg Injection : Each 1 mL contains 0.1 mL of concentrated extract of Viscum album (host tree: Malus) (1→50)
Abnobaviscum M 20 mg Injection : Each 1 mL contains 1 mL of concentrated extract of Viscum album (host tree: Malus) (1→50)

Indications and Therapeutic Effects

Treatment of tumors (including malignant tumor diseases accompanied by hematopoietic disorders), Prevention of recurrence after tumor surgery, Precancerous lesions

Dosage and Administration

Administer subcutaneously according to the following dosages.

1. Initial Phase
Unless otherwise prescribed, use 1 mL of Abnobaviscum injection at the specified concentration. Initially, begin treatment by administering 1 mL of Abnobaviscum injection 0.02 mg three times a week. Then gradually increase the dosage until reaching the concentration (0.02 mg, 0.2 mg, 2 mg, 20 mg) that produces the optimal response.The optimal concentration and dosage should be determined individually by the physician, observing the following responses.
- 1) Changes in the patient’s condition
  
  - On the day of administration, fatigue, tremors, discomfort, headache, and temporary dizziness may occur, but these are not signs of drug intolerance. Rather, they may indicate that the drug is working effectively and could be a sign that the dosage is too high. If such symptoms persist until the next day or exceed tolerable levels, it is recommended to reduce the concentration or dosage.
  
  - If improvements are observed in overall health (increased appetite and weight, normalized sleep, warmth, performance capacity), mental state (improved mood, increased motivation and initiative), and pain relief, the dosage is likely within the optimal range.
- 2) Temperature Response
  
  Several hours after administration, a temperature rise above average is observed, such as an increase of 0.5°C or more in average body temperature. In cases of tumor-related fever, lower doses should be administered periodically to normalize temperature.
- 3) Immune Response
  
  Observations may include an increase in white blood cell count (especially absolute lymphocytes and eosinophils), improvement in cellular immunity in recall antigen tests, or lymphocyte subset measurements.
- 4) Local Inflammatory Response
  
  A localized inflammatory reaction up to 5 cm in diameter may occur at the injection site.
2. Maintenance Phase
- 1) Unless otherwise prescribed, treatment can start with Abnobaviscum injection 0.02 mg, and the dosage can be increased stepwise to 0.2 mg, 2 mg, and 20 mg, administered 2–3 times per week.
- 2) Since a strong reaction may occur when increasing to the next concentration, it is advisable to first administer half or one-third of the next 1 mL ampoule. if a strong reaction occurs with Abnobaviscum 0.02 mg, the injection frequency should be adjusted or switched to Abnobaviscum extracted from a different host tree.
  In such cases, it is recommended to use 0.5 mL or 0.3 mL of Abnobaviscum injection with a graduated 1 mL syringe.
- 3) Dosage adjustment may be necessary during radiation therapy, chemotherapy, hormone therapy, or after surgery, as individual responses may vary.
- 4) o prevent habituation to the drug, alternate lower concentrations or adjust the injection schedule.
- 5) It is recommended to review the dosage every 3–6 months based on patient response and tumor activity.
3. Frequency of Administration
Administer subcutaneously 2–3 times per week.
4. Method of Administration
- 1) If possible, administer subcutaneously near the tumor or metastasis site.
  If not possible, change the injection site (e.g., abdominal skin, upper arm, thigh).
  Do not inject into inflamed areas or radiation-treated sites, and ensure injections are given subcutaneously.
- 2) Do not mix this drug with other medications in the same syringe.
- 3) Do not store opened ampoules after use.
5. Duration of Administration
- 1) In principle, there is no limit to the duration of administration. The treatment duration should be determined by the physician based on the risk of metastasis or recurrence, as well as the patient’s health condition and test results.
- 2) If the patient’s condition improves, reduce administration to twice a week after two years, adopt an 8-week treatment followed by a 4-week break after three years, and discontinue after seven years if the prognosis remains favorable.
- Treatment should continue even during travel or holidays.
6. Patients with Renal Impairment
Data are insufficient to determine dosage in patients with renal impairment.
To date, there is no established need for dosage adjustment.

LB Abnoba

LB Abnoba

Love & Care

Abnobaviscum M Injection 0.02mg/0.2mg/2mg/20mg

Abnobaviscum M Injection
0.02mg/0.2mg/2mg/20mg